Skip to main content

Table 1 Baseline characteristics of replication cohorts before and after matching

From: Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)

 

Before matching

After matching

Demographic or disease characteristic

VASST cohort

SPH cohort

VASST and SPH combined

DrotAA(n = 103)

Control(n = 370)

P value

DrotAA(n = 38)

Control(n = 227)

P value

DrotAA(n = 130)

Control a

(n = 286)

P value

Age

         

Mean ± SD

57.6 ± 15.6

62 ± 15.4

0.009

54.6 ±20.1

61 ± 14.9

0.072

58.4 ± 15.4

58.7 ± 15.3

0.886

Women (percentage of patients)

35.9%

41.4%

0.32

44.7%

33.5%

0.178

40%

36.8%

0.596

APACHE II score

         

Mean ± SD

27 ± 7.4

0.253

25.7 ± 6.4

22.9 ± 7.2

0.02

27.1 ± 5.8

27 ± 5.9

0.862

 

Medical (percentage of patients)

85.4%

76.5%

0.051

89.5%

83.3%

0.332

86.2%

79.4%

0.106

Organ failure (percentage of patients)

         

Cardiovascular

100%

100%

1

84.2%

82.4%

0.783

95.4%

96.2%

0.418

Respiratory

85.4%

85.4%

0.994

94.7%

93%

0.686

86.9%

86%

0.71

Renal

61.2%

46.2%

0.007

47.4%

46.3%

0.899

59.2%

55.5%

0.172

Hematologic

23.3%

19.5%

0.391

13.2%

13.7%

0.934

19.2%

15.1%

0.292

Ventilation (percentage of patients)

98.1%

93.5%

0.073

100%

89.4%

0.036

99.2%

99.2%

1

Caucasian (percentage of patients)

80.6%

83.2%

0.528

NA

NA

 

NA

NA

 
  1. aWeighted values for control group.